Compare
Maze Therapeutics, Inc. vs Scholar Rock Holding Corp vs Allogene Therapeutics, Inc. vs Sana Biotechnology, Inc.
| Latest fiscal year | Maze Therapeutics, Inc. MAZE | Scholar Rock Holding Corp SRRK | Allogene Therapeutics, Inc. ALLO | Sana Biotechnology, Inc. SANA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $0 | $0 | n/a |
| Revenue growth (YoY) | n/a | n/a | -100.0% | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | n/a |
| Net margin | n/a | n/a | n/a | n/a |
| Net income | -$131.12M | -$377.94M | -$190.89M | -$244.17M |
| EPS (Diluted) | -$3.05 | -$3.29 | -$0.87 | -$0.96 |
| Operating cash flow | -$111.94M | -$300.04M | -$149.25M | -$143.83M |
| Free cash flow | -$112.73M | -$300.64M | -$149.63M | -$144.77M |
| Cash & equivalents | $189.25M | $323.53M | $51.69M | $71.87M |
| Total assets | $397.13M | $404.27M | $415.90M | $416.89M |
| Total liabilities | $42.16M | $158.78M | $123.36M | $256.01M |
| Shareholders' equity | $354.97M | $245.49M | $292.54M | $160.88M |
| Return on year-end equity | -36.9% | -154.0% | -65.3% | -151.8% |
| Shares outstanding | 49.34M | 108.46M | 229.41M | 266.73M |
Revenue, most recent five fiscal years
| Fiscal year | Maze Therapeutics, Inc. | Scholar Rock Holding Corp | Allogene Therapeutics, Inc. | Sana Biotechnology, Inc. |
|---|---|---|---|---|
| Latest | $167.50M Ended 2024-12-31 | $0 Ended 2025-12-31 | $0 Ended 2025-12-31 | n/a |
| 1 year earlier | n/a | n/a | $22.0K Ended 2024-12-31 | n/a |
| 2 years earlier | n/a | n/a | $95.0K Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | $33.19M Ended 2022-12-31 | $156.0K Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | $18.82M Ended 2021-12-31 | $114.09M Ended 2021-12-31 | n/a |